The up-regulation of Mcl-1 expression is a major mechanism of cancer cell survival and 12 therapy resistance. However, the underlying molecular mechanism remains incompletely 13 understood, limiting the number of druggable approaches to selectively inhibit Mcl-1 function. In this 14 study, we designed and employed a novel mechanistic high-throughput screening system to 15 selectively uncover post-translational modulators of Mcl-1. We generated a cell-based high-16 throughput screening assay in which myeloid leukemia K562 cells constitutively express Mcl-1 or 17 Bcl-xL fused with luciferase (Luc-Mcl-1 or Luc-Bcl-xL, respectively) under a viral promoter. 1,650 18 bioactive compounds were screened for their ability to selectively induce Mcl-1 down-regulation in 19 a 2-hour assay. A family of niclosamide derivatives were eventually identified for their remarkable 20 ability to decrease Mcl-1 protein stability, exemplified by N007. These salicylate derivatives did not 21 alter Mcl-1 mRNA levels, but selectively induced proteasome-dependent Mcl-1 down-regulation 22 independent of Noxa, Mule, or GSK3β. We also demonstrate that N007 potently induced cell death 23 in leukemia cell lines, including those resistant to Bcl-2 inhibitors. Our work highlights the versatility 24 of the mechanistic high-throughput screening approach as a valuable tool in identifying novel agents 25 with the ability to down-regulate proteins crucial to human diseases.
under investigation for a myriad of antitumor activities. Niclosamide has been described to antagonize 202 STAT3 or Bcl-2 family proteins but its molecular mechanism has not been described 
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Kasumi-1 KG-1 U937 HL60 H929 H23 H460 N007 3.7 5.6 1.1 1.7 1.3 2.4 1.9 ABT-199 0.1 6.7 9.0 0.2 > 10 > 10 > 10 ABT-737 0.1 1.5 3.9 0.2 > 10 > 10 > 10 support in this study.
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